All about Drugs Live by Dr Anthony Melvin Crasto
Adagrasib Formula C32H35ClFN7O2 cas 2326521-71-3 Mol weight 604.1174 Antineoplastic Disease Non-small cell lung cancer 2022/12/12 FDA APPROVED, KRAZATI (Mirati Therapeutics) MRTX-849 MRTX849 KRAS G12C inhibitor MRTX849 Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer.[1][2] Adagrasib is an inhibitor of the RAS GTPase family.[1] It is taken by mouth.[1] It is being developed by Mirati Therapeutics.[1][3] …
Olutasidenib FT-2102 FT2102 C18H15ClN4O2 354.79 CAS1887014-12-1 Rezlidhia (Forma Therapeutics) SYN Caravella JA, et al. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. FDA 12/1/2022, To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) …
Mirvetuximab soravtansine-gynx FDA 11/14/2022, To treat patients with rTo treat patients with recurrent ovarian cancer that is resistant to platinum therapy that is resistant to platinum therapy, Elahere FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer https://www.biochempeg.com/article/315.html 4846-85a8-48171ab38275 FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer November 15, 2022 Kristi Rosa The FDA has granted …
(Light chain) DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (Heavy chain) QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN …
Daxibotulinumtoxin A FDA APPROVED 2022 2022/9/7, Daxxify Formula C6708H10359N1729O1995S32 CAS 93384-43-1 Mol weight 148171.4934 Daxibotulinumtoxin A-lanm Treatment of galbellar lines, cervical dystonia, lateral canthal lines, migraine headaches and hyperhidrosis DeveloperRevance Therapeutics; Shanghai Fosun Pharmaceutical ClassAnalgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin …
Futibatinib フチバチニブ Formula C22H22N6O3 CAS 1448169-71-8 Mol weight 418.4485 2022/9/30 FDA APPROVED, Lytgobi Antineoplastic, Receptor tyrosine kinase inhibitor Disease Cholangiocarcinoma (FGFR2 gene fusion) 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one TAS-120, TAS 120, TAS120; Futibatinib Futibatinib, also known as TAS-120 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor TAS-120 selectively and irreversibly …
Gadopiclenol ガドピクレノール; Formula C35H54N7O15. Gd CAS 933983-75-6 Mol weight 970.0912 FDA APPROVED 2022/9/21, Elucirem Diagnostic agent (MR imaging), WHO 10744, P 03277, UNII: S276568KOY EluciremTM; G03277; P03277; VUEWAY (alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium OriginatorGuerbet ClassDiagnostic agents; Gadolinium-containing contrast agents; Macrocyclic compounds; Propylamines; Pyridines Mechanism of ActionMagnetic resonance imaging enhancers RegisteredCNS disorders Phase IIIUnspecified Phase IILiver cancer 21 Sep 2022Registered for CNS disorders (Diagnosis) …
Eflapegrastim エフラペグラスチム; Molecular Formula C15-H28-N2-O6(C2-H4-O)n Molecular Weight 376.4468 Formula C3070H4764N806O927S23.(C2H4O)n UNII: UT99UG9QJX HM10460A SPI-2012 HNK460 Reducing neutropenia and the incidence of infecton in patients with cancer (2S)-1-{3-[2-(3-{[(1S,2R)-1-carboxy-2-hydroxypropyl]amino}propoxy)ethoxy]propyl}pyrrolidine-2-carboxylic acid APPROVED FDA 2022/9/9, Rolvedon CAS: 1384099-30-2 LAPS-GCSF, ROLONTIS Antineutropenic, Leukocyte growth factor Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, 1-ether with immunoglobulin G4 [1-[1-(3-hydroxypropyl)proline]] (human Fc fragment), (3→3′)–disulfide with immunoglobulin G4 (human Fc fragment), 1′′-ether with …
Terlipressin acetate テルリプレシン酢酸塩 C52H74N16O15S2. (C2H4O2)x CAS: 914453-96-6 ACETATEFREE FORM 14636-12-5 Terlipressin acetate (JAN); Heamopressin (TN); Terlivaz (TN) Cardiovascular agent Antidiuretic, Vasoconstrictor, Arginine vasopressin receptor agonist USFDA APPROVED 2022/9/14 An inactive peptide prodrug that is slowly converted in the body to lypressin. It is used to control bleeding of ESOPHAGEAL VARICES and for the treatment of HEPATORENAL …
Betibeglogene autotemcel ベチベグロゲンアウトテムセル 2022/8/17, FDA APPROVED Zynteglo Cellular therapy product Treatment of betathalassemia BB305 LVV, bb 1111 BB305 transduced SCD CD34+ HSCs bb1111 LentiGlobin BB305 LVV-transduced autologous SCD CD34+ HSCs bb1111 LentiGlobin drug product for SCD LentiGlobin drug product for sickle cell disease LentiGlobin for SCD bb1111 Betibeglogene autotemcel, sold under the brand name Zynteglo, is a …